Dolby Laboratories (DLB) reported second-quarter 2026 results with revenue up year‑over‑year and a mixed beat versus estimates: revenue rose 7.05% to $395.6 million, about 1.5% above the consensus estimate of $389.7 million (roughly a $6.0 million beat).
Cash flow and balance-sheet items showed some softness despite profitable operations.
Market reaction and other notable items:
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Dolby Laboratories Insider Trading Activity
Dolby Laboratories insiders have traded $DLB stock on the open market 19 times in the past 6 months. Of those trades, 0 have been purchases and 19 have been sales.
Here’s a breakdown of recent trading of $DLB stock by insiders over the last 6 months:
- KEVIN J YEAMAN (President and CEO) has made 0 purchases and 7 sales selling 104,583 shares for an estimated $7,001,136.
- JOHN D COULING (SVP, Entertainment) has made 0 purchases and 3 sales selling 20,104 shares for an estimated $1,340,170.
- MARK ANDREW SHERMAN (EVP, Gen. Counsel & Secretary) has made 0 purchases and 4 sales selling 16,100 shares for an estimated $1,079,438.
- SHRIRAM REVANKAR (SVP, Advanced Technology Group) has made 0 purchases and 2 sales selling 6,000 shares for an estimated $395,070.
- TONY A PROPHET sold 3,300 shares for an estimated $223,904
- RYAN NICHOLSON (VP, CAO and Corp. Controller) sold 2,667 shares for an estimated $177,022
- EMILY ROLLINS sold 1,000 shares for an estimated $60,080
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
Dolby Laboratories Hedge Fund Activity
We have seen 200 institutional investors add shares of Dolby Laboratories stock to their portfolio, and 208 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY removed 679,901 shares (-9.9%) from their portfolio in Q4 2025, for an estimated $43,663,242
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 580,496 shares (-76.2%) from their portfolio in Q4 2025, for an estimated $37,279,453
- AQR CAPITAL MANAGEMENT LLC removed 448,310 shares (-34.7%) from their portfolio in Q4 2025, for an estimated $28,790,468
- PACER ADVISORS, INC. removed 443,897 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $28,507,065
- BOSTON TRUST WALDEN CORP removed 435,704 shares (-49.2%) from their portfolio in Q1 2026, for an estimated $26,168,382
- D. E. SHAW & CO., INC. added 401,788 shares (+inf%) to their portfolio in Q4 2025, for an estimated $25,802,825
- ALYESKA INVESTMENT GROUP, L.P. added 365,573 shares (+inf%) to their portfolio in Q4 2025, for an estimated $23,477,098
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Dolby Laboratories Analyst Ratings
Wall Street analysts have issued reports on $DLB in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barrington Research issued a "Outperform" rating on 01/30/2026
- Rosenblatt issued a "Buy" rating on 01/30/2026
To track analyst ratings and price targets for Dolby Laboratories, check out Quiver Quantitative's $DLB forecast page.
Dolby Laboratories Price Targets
Multiple analysts have issued price targets for $DLB recently. We have seen 2 analysts offer price targets for $DLB in the last 6 months, with a median target of $87.5.
Here are some recent targets:
- Patrick Sholl from Barrington Research set a target price of $90.0 on 04/27/2026
- Steven Frankel from Rosenblatt set a target price of $85.0 on 01/30/2026
